From the Office of the NSW Chief Scientist & Engineer, first released on their LinkedIn:
The mission of the National Imaging Facility is to provide cutting-edge imaging capabilities to Australian researchers and industry, which will make significant impacts on major health challenges and accelerate Australian innovation. Recent investment from the NSW Government supports new radiochemistry facilities and capability, as well as growing imaging expertise in NSW that addresses critical imaging priorities for NSW. This case study demonstrates the importance of open access research infrastructure to solve critical health challenges, specifically therapeutics for Alzheimer’s disease.
It is an excellent look at why advancing human imaging with the support of national infrastructure (through Australian Government Department of Education’s NCRIS funding) and NSW research facilities add up to make such a difference for Australians’ lives.
Donanemab, developed by Lilly, is the first disease-modifying treatment for early-stage Alzheimer’s disease to be approved for use in Australia. NIF supported its development by providing MRI and PET imaging services to help generate critical evidence that contributed to its approval.
We are grateful to the Office of the NSW Chief Scientist & Engineer for highlighting this work, to Prof Michael Breakspear and his co-director Saad Ramadan, and to the Hunter Medical Research Institute (HMRI) Imaging Centre for hosting.